ArticleOpen heart2026
Prognostic value of cardiac fibroblast activation heterogeneity assessed by FAPI PET radiomics in hypertrophic cardiomyopathy: a proof-of-concept study.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death (SCD), and myocardial fibrosis plays a central role in the pathophysiology process. Radiolabelled fibroblast activation protein inhibitor (FAPI) positron emission tomography computed tomography (PET) imaging enables visualisation of activated fibroblasts and may detect earlier stages of myocardial fibrosis than conventional structural imaging. However, most previous studies have relied on simple uptake-based metrics, potentially underusing the quantitative information contained in PET images.
objectiveTo develop and internally validate a radiomics model based on FAPI PET imaging for stratifying predicted 5-year SCD risk in patients with HCM.
methodsA total of 92 patients with HCM from two centres who underwent FAPI PET/CT or PET/cardiac magnetic resonance (CMR) were retrospectively included. Radiomics features were extracted from myocardial regions of interest and selected using elastic net regression. A radiomics model was constructed and evaluated using bootstrap internal validation. Model performance was compared with a conventional imaging metric (FAPI amount). Sensitivity analysis was performed to assess robustness across imaging modalities.
resultsTwo radiomics features were selected to construct the model. The apparent area under the receiver operating curve of the radiomics model was 0.839, which decreased to 0.772 after bootstrap correction and became comparable to the conventional metric. Sensitivity analysis demonstrated stable model performance after excluding PET/CMR data.
conclusionFAPI PET-based radiomics is feasible for quantifying myocardial fibroblast activation heterogeneity and shows potential for predicted SCD risk stratification in HCM. These findings should be interpreted as proof-of-concept and require validation in larger prospective cohorts with clinical endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.